Clearance Summary
ACCURUN 140 RUBELLA IGG POSITIVE CONTROL received FDA 510(k) clearance under submission number K972986, sponsored by Boston Biomedica, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 1997-10-08.
- Submission: K972986
- Applicant / Sponsor: Boston Biomedica, Inc.
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class I
- Regulation citation: 21 CFR 862.1660
- Decision date: 1997-10-08
Classification & Regulation
This clearance is catalogued under FDA product code MJX and 21 CFR 862.1660, within the Clinical Chemistry review panel as a Class I device.